Trial · NCT03393780
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Use of algorithm-based individualised dosing regimen to decide daily dose of REKOVELLE® | At consultation visit where the daily dose of REKOVELLE® is decided | Calculated with body weight in kilograms or pounds and AMH serum level in pmoL/L or ng/ml to define the daily dose of REKOVELLE® in micrograms |
| Primary | Use of the dosing App | At consultation visit where the daily dose of REKOVELLE® is decided | Use of the Ferring developed dosing app for the daily dose calculation by answering yes/no to a questionnaire |
| Primary | Daily dose of REKOVELLE® in micrograms | From day 1 up to day 20 of REKOVELLE® stimulation | |
| Primary | Number of days of treatment with REKOVELLE® | From day 1 up to day 20 of REKOVELLE® stimulation | Adjusted during the stimulation based on blood sample of Oestrogen levels and number of follicles (at the discretion of the investigator) |
| Primary | Day of REKOVELLE® stimulation start | At the day of the first REKOVELLE® injection during the ovarian stimulation treatment | The time point of the start of the stimulation is decided at the discretion of the investigator |
| Primary | Day of REKOVELLE® stimulation end | At the day of the last REKOVELLE® injection during the ovarian stimulation treatment | The time point of the end of the stimulation is decided at the discretion of the investigator |
| Primary | Type of GnRH used for Lutenizing Hormone(LH) surge suppression | At consultation visit where the LH surge suppression protocol is decided | Defined as a choice between GnRH agonist and GnRH antagonist |
| Primary | Day of LH surge suppression protocol start | At the day of the first GnRH administration during the ovarian stimulation treatment | The time point of the start of LH surge suppression is decided at the discretion of the investigator |
| Primary | Day of LH surge suppression protocol end | At the day of the last GnRH administration during the ovarian stimulation treatment | The time point of the end of LH surge suppression is decided at the discretion of the investigator |
| Primary | Type of drug used for the triggering of follicle maturation | At consultation visit where the triggering of follicle maturation protocol is decided | Decided as a choice between hCG and/or GnRH |
| Primary | Date of administration of hCG and/or GnRH for follicle maturation | At the day of administration (at the discretion of the investigator) | Date when the investigator decides to trigger the final follicle maturation |
| Primary | Type of drug used for Luteal phase support | From ovum pick-up day (the length of luteal phase support is decided at the discretion of the investigator) | Decided as a choice between Progesterone, Oestrogen and hCG |
| Primary | Parameters used to define the daily dose of REKOVELLE® in case a new assisted reproductive technology treatment is initiated | At consultation visit where the ovarian stimulation treatment strategy is decided | According to the Summary of Product Characteristics, the daily dose can be increased or decreased for subsequent cycles based on the patient response to the initial treatment cycle. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03393780/registered